Prognosis
Eisai ‘Extremely Confident’ of Winning US Approval for Alzheimer’s Drug
- Sees US approval for treatment leading to Medicare coverage
- More data due out next month, decision seen in January
This article is for subscribers only.
Japanese drugmaker Eisai Co. is “extremely confident” of winning full US approval for its experimental Alzheimer’s drug, paving the way to broad coverage under Medicare insurance for elderly Americans, Chief Executive Officer Haruo Naito said.
“The data is indisputable,” Naito said in an interview in Tokyo. “The drug met primary and secondary endpoints perfectly and has a manageable safety profile. We are extremely confident.”